Globalpharma, the UAE’s premier pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, has teamed up with India-based ZIM Laboratories to introduce Oral Dispersible Film (ODF) technology to its growing portfolio.
This pioneering drug technology has already secured EU Good Manufacturing Practice (EU-GMP) certification, ensuring its adherence to the highest international quality and safety standards.
The partnership was revealed during AIM Congress 2025, which is currently being held in Abu Dhabi. This move highlights the UAE’s growing influence in global pharmaceutical innovation and its commitment to driving innovation in healthcare industry.
The agreement was signed by Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma and Zulfiquar Kamal, Promoter & Finance Director at ZIM Labs in the presence of Dr. Mariam Galadari, Board Member, Globalpharma.
The signing ceremony was also witnessed by Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade and Chairman of the Board of Emirates Drug Establishment (EDE).
Dr. Basem Al-Barahmeh, Globalpharma’s General Manager, presented a keynote on the UAE’s emergence as a pharmaceutical manufacturing powerhouse. Additionally, Dr. Geeta Gujaran, Globalpharma’s Site Head, shared valuable insights on the “Leaders’ Panel: Manufacturing 2030 – Key Trends Shaping the Industry.”
Mohammed Saeed Al Raqbani General Manager – Dubai Investments Industries and Masharie Board Director – Globalpharma
“This partnership with ZIM Labs is a transformative step for Globalpharma. By bringing EU-certified ODF technology to the UAE, we are strengthening the region’s pharmaceutical capabilities and advancing patient-centric treatment options. This move aligns with our vision to invest in innovations that elevate regional healthcare standards while positioning the UAE as a leader in advanced drug manufacturing.”
ODFs transform the drug industry by offering thin, fast-dissolving strips that melt in the mouth without water, making them ideal for children, elderly patients, and those with swallowing difficulties. ZIM Labs’ proprietary technology enables the smooth integration of medications into these stable, rapid-acting films, enhancing patient compliance and treatment efficacy.
Dr. Basem Al-Barahmeh stated that, “By acquiring and localizing ODF production within UAE facility, Globalpharma is not only introducing innovative treatments but also setting a benchmark for pharmaceutical manufacturing in the region. Our dedicated production line, with a growing portfolio of ten ODF products, puts us at the forefront of this technology in the Middle East. This step reinforces the UAE’s role as a key player in global pharma advancements.”
Zulfiquar Kamal added that, “This technology transfer with globalpharma is a significant milestone in our mission to expand access to patient-friendly drug delivery systems around the world. Our EU-GMP certified ODF technology combined with Globalpharma’s regional reach and manufacturing strength, will set a new benchmark for pharmaceutical innovation in the GCC.”
ZIM Laboratories Limited is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company has cutting-edge in-house R&D capabilities, providing pioneering drug delivery solutions by leveraging proprietary technology platforms.
The pharmaceutical company is committed to enhancing patient convenience and treatment adherence. Furthermore, it is listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.
